Latest Headlines

Latest Headlines

Hong Kong drugstores attract Chinese customers for cancer, hep C drugs

Many shoebox-sized drugstores in Hong Kong are magnets for mainland Chinese seeking access to cutting-edge oncology and hepatitis C treatments without a prescription because they are either highly expensive or not available at home in the latest twist of cross-border healthcare buying, Bloomberg reports.

BMS' Opdivo gets a jump on Keytruda with another early FDA approval

Ready for the lung cancer showdown between Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo? It's here, and way ahead of schedule.

California sets strictest U.S. standards for antibiotics use in livestock

On Oct. 10, California Gov. Jerry Brown signed a bill that prohibits the use of antibiotics for fattening up farm animals and that requires the drugs to be prescribed by licensed veterinarians. It is the most restrictive law to date in the U.S. aimed at stemming the rise of antibiotic-resistant infections.

CIMB says Malaysian pharmas have scope to adjust to TPP changes

CIMB Equities Research said last week the Trans-Pacific Partnership could negatively impact the Malaysian pharmaceutical sector, but those effects won't be felt any time soon, according to a report in The Nation.

U.S. FDA approvals for Indian pharmas jump 50%

Indian pharmaceutical firms got some good news last week when it was reported that during the period from July to September there was a 50% gain in the number of abbreviated new drug approvals (ANDAs) by the U.S. FDA, Bloomberg TV India reported.

FDA seeks comments on potential scheduling change for ketamine

The World Health Organization came under attack earlier this year from veterinarians concerned that it might reclassify the narcotic ketamine, thereby making it difficult to obtain.

FDA signs off on BioFire Diagnostics' rapid meningitis test

BioMérieux's BioFire Diagnostics got an FDA OK for its rapid meningitis and encephalitis test, a feather in the company's cap as it diversifies its portfolio and ramps up business in an increasingly competitive market.

HK-listed Luye shares gain as U.S. FDA NDA submission for LY03004 on track

Hong Kong-listed Luye Pharma's New Drug Application to the U.S. FDA for candidate LY03004 (risperidone), aimed at treating schizophrenia and bipolar disorders, is under way without the agency requesting further clinical trials,  Barron's  reported, sending shares higher on Friday.

India's GVK apparently lost its quality reputation to love, report says

An extramarital affair has cost GVK Biosciences millions of dollars in lost opportunity and brought unwanted scrutiny of its testing procedures and a ban on the marketing of about 700 generic drugs tested at a facility where the affair began, according to a report in The Hindu newspaper.

With FDA 'breakthrough' in hand, Eli Lilly shoots for accelerated abemaciclib OK

Eli Lilly's would-be rival to Pfizer's Ibrance (palbociclib) just gained an inside track at the FDA. Regulators handed Lilly the coveted "breakthrough therapy" designation for abemaciclib, another CDK 4/6 inhibitor with big plans for carving out a niche among patients with advanced breast cancer.